Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06213649 · ClinicalTrials.gov registry record · Phase 3
Parasitic Ulcer Treatment Trial
A Phase 3 study of Acanthamoeba Keratitis, sponsored by Jeremy Keenan, MD, MPH.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
- 16
- Study locations
NCT06213649: Recruiting Phase 3 study of Acanthamoeba Keratitis, sponsored by Jeremy Keenan, MD, MPH.
NCT06213649 is a Phase 3 study of Acanthamoeba Keratitis that is actively recruiting participants, run by Jeremy Keenan, MD, MPH. The registered enrollment target is 232 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06213649, a Phase 3 study of Acanthamoeba Keratitis, is actively recruiting participants, sponsored by Jeremy Keenan, MD, MPH.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
- 16
- Study locations
Study Summary
The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers with evidence of acanthamoeba keratitis will be eligible for the trial if there is evidence of ocular inflammation after 4 weeks of anti-amoebic therapy. Those who agree to participate will be randomized to one of two treatment groups: * Group 1: Topical corticosteroid * Group 2: Topical placebo
Primary Outcome
Best corrected visual acuity
Conditions Studied
Interventions
- DRUG Polyhexamethylene biguanide (PHMB)
- DRUG Topical corticosteroid
- OTHER Topical placebo
Study Locations (16)
Florida
- University of Florida - Gainesville
- University of Miami - Miami
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Other
- Federal University of São Paulo - São Paulo
- Moorfields Eye Hospital - London
Tamil Nadu
- Aravind Eye Hospital - Coimbatore
- Aravind Eye Hospital - Madurai
California
- University of California, San Francisco - San Francisco
Illinois
- University of Illinois, Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
What NCT06213649 shows while recruiting
NCT06213649 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Acanthamoeba Keratitis appearing as the primary indexed condition, and to 3 interventions - of which Polyhexamethylene biguanide (PHMB) is the first listed.
NCT06213649 lists 16 locations in 12 states (Florida, Pennsylvania, Other).
Frequently Asked Questions
What is clinical trial NCT06213649 about?
NCT06213649 is a clinical study titled "Parasitic Ulcer Treatment Trial". The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers...
What is the current status of trial NCT06213649?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2024-07-01. Estimated completion is 2028-07.
What conditions does trial NCT06213649 study?
This clinical trial studies the following conditions: Acanthamoeba Keratitis.
What interventions are being tested in trial NCT06213649?
The interventions under investigation include: Polyhexamethylene biguanide (PHMB) (DRUG), Topical corticosteroid (DRUG), Topical placebo (OTHER).
Who is sponsoring clinical trial NCT06213649?
This trial is sponsored by Jeremy Keenan, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06213649 being conducted?
This trial has 16 study locations across California, Florida, Illinois, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06213649's enrollment target sits among peer trials
232 1299th of 2000 higher than 701 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI